Diabetes patients taking Avandia or Actos are two times as likely to develop heard problems, according to a report published in the August issue of Diabetes Care.
An advisory panel hearing Monday will examine whether Avandia’s cardiovascular risks warrant a stronger warning label following a U.S. government review found Avandia’s heart risks are far higher than Actos’..
Avandia (rosiglitazone) and Actos (pioglitazone) are from the same family of diabetes drugs and used by more than 3 million diabetic patients across the United States.
For more information on this subject, please refer to our section on Drugs, Medical Devices, and Implants.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.